After Local Therapy for Esophageal Cancer, Should We Continue to Survey Patients and, If So, Why and How?

Restricted access

Jaffer A. Ajani, MD, an internationally recognized expert on gastrointestinal cancers, is Professor of Gastrointestinal Medical Oncology at MD Anderson Cancer Center and Chair of the NCCN Clinical Practice Guidelines in Oncology for Esophageal and Gastric Cancers. He has participated over the past 20 years in numerous trials using innovative combined modality therapies for localized gastric and esophageal cancers, and some of his work has led to the development of strategies of preoperative therapy for resectable upper gastrointestinal cancers.His current research focus is on developing programs to research the molecular markers for progression of Barrett’s metaplasia to adenocarcinoma. These research efforts involve multi-institutional collaboration with investigators at the University of Chicago, University of Pennsylvania, Mayo Clinic, and Yonsei University, in Seoul, Korea.In addition to his work with NCCN, Dr. Ajani participates actively in the International Society of Gastrointestinal Oncology is the editor of the Society’s journal, Gastrointestinal Oncology Research.The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.
  • 1.

    AllumWHStenningSPBancewiczJ. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol2009;27:50625027.

    • Search Google Scholar
    • Export Citation
  • 2.

    AjaniJABarthelJSBentremDJ. NCCN Clinical Practice Guidelines in Oncology for esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw2011;9:830887.

    • Search Google Scholar
    • Export Citation
  • 3.

    van HagenPHulshofMCvan LanschotJJ. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med2012;366:20742084.

    • Search Google Scholar
    • Export Citation
  • 4.

    CooperJSGuoMDHerskovicA. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA1999;281:16231627.

    • Search Google Scholar
    • Export Citation
  • 5.

    DorthJAPuraJAPaltaM. Patterns of recurrence after trimodality therapy for esophageal cancer. Cancer2014;120:20992105.

  • 6.

    SudoKTaketaTCorreaAM. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol2013;31:43064310.

    • Search Google Scholar
    • Export Citation
  • 7.

    SudoKXiaoLWadhwaR. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol2014;32:34003405.

    • Search Google Scholar
    • Export Citation
  • 8.

    LouFSimaCSAdusumilliPS. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol2013;8:15581562.

  • 9.

    TaketaTSudoKCorreaAM. Post chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netwin press.

    • Search Google Scholar
    • Export Citation
  • 10.

    ShiozakiHSudoKXiaoL. Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. Oncology2014;86:336339.

    • Search Google Scholar
    • Export Citation
  • 11.

    OppedijkVvan der GaastAvan LanschotJJ. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol2014;32:385391.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 16 16 2
PDF Downloads 6 6 0
EPUB Downloads 0 0 0